Download PDF
Digestive Disease Interventions
DOI: 10.1055/s-0044-1800822
Review Article

Role of Local Therapy for Metastatic Gastrointestinal Malignancies

Caressa Hui 
1   Department of Radiation Oncology, University of California Irvine, Irvine, California
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Oligometastatic disease is an increasingly recognized intermediate tumor state between locally confined and widely metastatic cancer. Oligometastatic gastrointestinal (GI) malignancies represent a heterogeneous spectrum of disease, and treatment strategies are tailored to each patient and are impacted by multiple factors. Recent advances in systemic therapies, imaging techniques, and local treatment modalities have revolutionized cancer treatment and present new opportunities to improve outcomes in patients with a limited burden of metastatic disease. However, there is currently a lack of consensus and robust literature to guide patient selection and treatment strategies, including the optimal role and timing of local therapies as adjuncts to standard-of-care systemic therapy. The intent of this review is to comprehensively discuss the role of local therapies in the modern management of oligometastatic GI malignancies.

Keywords

oligometastatic - radiotherapy - stereotactic - SBRT - oligometastases


Publication History

Received: 30 September 2024

Accepted: 07 November 2024

Article published online:
04 December 2024

© 2024. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol 1995; 13 (01) 8-10
    CrossrefPubMedSearch in Google Scholar
  • 2 Palma DA, Olson R, Harrow S. et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet 2019; 393 (10185): 2051-2058
    CrossrefPubMedSearch in Google Scholar
  • 3 Palma DA, Olson R, Harrow S. et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET Phase II Randomized Trial. J Clin Oncol 2020; 38 (25) 2830-2838
    CrossrefPubMedSearch in Google Scholar
  • 4 Howlader N, Noone AM, Krapcho M. et al. SEER Cancer Statistics Review, 1975–2017. SEER. April 2020 . Accessed September 10, 2024 at: https://seer.cancer.gov/csr/1975_2017/index.html
    PubMedSearch in Google Scholar
  • 5 Sun JM, Shen L, Shah MA. et al; KEYNOTE-590 Investigators. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet 2021; 398 (10302): 759-771
    CrossrefPubMedSearch in Google Scholar
  • 6 Doki Y, Ajani JA, Kato K. et al; CheckMate 648 Trial Investigators. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med 2022; 386 (05) 449-462
    CrossrefPubMedSearch in Google Scholar
  • 7 Bang YJ, Van Cutsem E, Feyereislova A. et al; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376 (9742) 687-697
    CrossrefPubMedSearch in Google Scholar
  • 8 Janjigian YY, Kawazoe A, Yañez P. et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature 2021; 600 (7890) 727-730
    CrossrefPubMedSearch in Google Scholar
  • 9 Janjigian YY, Shitara K, Moehler M. et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 2021; 398 (10294): 27-40
    CrossrefPubMedSearch in Google Scholar
  • 10 Kroese TE, Christ SM, van Rossum PSN. et al. Incidence and survival of patients with oligometastatic esophagogastric cancer: a multicenter cohort study. Radiother Oncol 2022; 173: 269-276
    CrossrefPubMedSearch in Google Scholar
  • 11 Quint LE, Hepburn LM, Francis IR, Whyte RI, Orringer MB. Incidence and distribution of distant metastases from newly diagnosed esophageal carcinoma. Cancer 1995; 76 (07) 1120-1125
    CrossrefPubMedSearch in Google Scholar
  • 12 Kroese TE, van Laarhoven HWM, Schoppman SF. et al; OMEC Collaborators. Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: a Delphi consensus study in Europe. Eur J Cancer 2023; 185: 28-39
    CrossrefPubMedSearch in Google Scholar
  • 13 Kroese TE, van Rossum PSN, Nilsson M. et al; OMEC-Working Group (Supplementary File 1). Study protocol for the OligoMetastatic Esophagogastric Cancer (OMEC) project: a multidisciplinary European consensus project on the definition and treatment for oligometastatic esophagogastric cancer. Eur J Surg Oncol 2023; 49 (01) 21-28
    CrossrefPubMedSearch in Google Scholar
  • 14 Kroese TE, Bronzwaer S, van Rossum PSN. et al; OMEC Collaborators. European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4). Eur J Cancer 2024; 204: 114062
    CrossrefPubMedSearch in Google Scholar
  • 15 Ohtsu A, Boku N, Muro K. et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol 1999; 17 (09) 2915-2921
    CrossrefPubMedSearch in Google Scholar
  • 16 Ishida K, Ando N, Yamamoto S, Ide H, Shinoda M. Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516). Jpn J Clin Oncol 2004; 34 (10) 615-619
    CrossrefPubMedSearch in Google Scholar
  • 17 Shinoda M, Ando N, Kato K. et al; Japan Clinical Oncology Group. Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303). Cancer Sci 2015; 106 (04) 407-412
    CrossrefPubMedSearch in Google Scholar
  • 18 Shi Z, Zhu X, Ke S. et al. Survival impact of concurrent chemoradiotherapy for elderly patients with synchronous oligometastatic esophageal squamous cell carcinoma: a propensity score matching and landmark analyses. Radiother Oncol 2021; 164: 236-244
    CrossrefPubMedSearch in Google Scholar
  • 19 Shi Z, Zhu X, Ruan C. et al. Evaluation of concurrent chemoradiotherapy for survival outcomes in patients with synchronous oligometastatic esophageal squamous cell carcinoma. JAMA Netw Open 2022; 5 (12) e2244619
    CrossrefPubMedSearch in Google Scholar
  • 20 Kroese TE, van Laarhoven HWM, Nilsson M. et al. Definition of oligometastatic esophagogastric cancer and impact of local oligometastasis-directed treatment: a systematic review and meta-analysis. Eur J Cancer 2022; 166: 254-269
    CrossrefPubMedSearch in Google Scholar
  • 21 Ji J, Liu Y, Bao Y, Men Y, Wang J, Hui Z. Effects of local treatment in combination with systemic therapy for advanced esophageal cancer: a systematic review and meta-analysis. Adv Radiat Oncol 2024; 9 (07) 101522
    CrossrefPubMedSearch in Google Scholar
  • 22 Liu Q, Zhu Z, Chen Y. et al. Phase 2 study of stereotactic body radiation therapy for patients with oligometastatic esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2020; 108 (03) 707-715
    CrossrefPubMedSearch in Google Scholar
  • 23 Zhao W, Ke S, Cai X. et al. Radiotherapy plus camrelizumab and irinotecan for oligometastatic esophageal squamous cell carcinoma patients after first-line immunotherapy plus chemotherapy failure: an open-label, single-arm, phase II trial. Radiother Oncol 2023; 184: 109679
    CrossrefPubMedSearch in Google Scholar
  • 24 Schizas D, Mylonas KS, Kapsampelis P. et al. Patients undergoing surgery for oligometastatic oesophageal cancer survive for more than 2 years: bootstrapping systematic review data. Interact Cardiovasc Thorac Surg 2020; 31 (03) 299-304
    CrossrefPubMedSearch in Google Scholar
  • 25 Smyth EC, Lagergren J, Fitzgerald RC. et al. Oesophageal cancer. Nat Rev Dis Primers 2017; 3: 17048
    CrossrefPubMedSearch in Google Scholar
  • 26 Liu Q, Chen J, Lin Y. et al. Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trial. Lancet Gastroenterol Hepatol 2024; 9 (01) 45-55
    CrossrefPubMedSearch in Google Scholar
  • 27 Guidelines With Evidence Blocks. . Stomach. NCCN. Accessed September 10, 2024 at: https://www.nccn.org/guidelines/guidelines-with-evidence-blocks
    PubMed
  • 28 Glimelius B, Ekström K, Hoffman K. et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997; 8 (02) 163-168
    CrossrefPubMedSearch in Google Scholar
  • 29 Wagner AD, Syn NL, Moehler M. et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2017; 8 (08) CD004064
    PubMedSearch in Google Scholar
  • 30 Then EO, Grantham T, Deda X, Ramachandran R, Gaduputi V. Metastatic gastric cancer to the colon. World J Oncol 2021; 12 (04) 127-131
    CrossrefPubMedSearch in Google Scholar
  • 31 Al-Batran SE, Homann N, Pauligk C. et al. Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: The AIO-FLOT3 Trial. JAMA Oncol 2017; 3 (09) 1237-1244
    CrossrefPubMedSearch in Google Scholar
  • 32 Sano T, Coit DG, Kim HH. et al. Proposal of a new stage grouping of gastric cancer for TNM classification: International Gastric Cancer Association staging project. Gastric Cancer 2017; 20 (02) 217-225
    CrossrefPubMedSearch in Google Scholar
  • 33 Japanese Gastric Cancer Association. Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition). Gastric Cancer 2023; 26 (01) 1-25
    CrossrefPubMedSearch in Google Scholar
  • 34 Fujitani K, Yang HK, Mizusawa J. et al; REGATTA Study Investigators. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol 2016; 17 (03) 309-318
    CrossrefPubMedSearch in Google Scholar
  • 35 Cui Y, Yu Y, Zheng S. et al. Does resection after neoadjuvant chemotherapy of docetaxel, oxaliplatin, and S-1 (DOS regimen) benefit for gastric cancer patients with single non-curable factor? a multicenter, prospective cohort study (Neo-REGATTA). BMC Cancer 2023; 23 (01) 308
    CrossrefPubMedSearch in Google Scholar
  • 36 Study Details | Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction | ClinicalTrials.gov. Accessed September 10, 2024 at: https://clinicaltrials.gov/study/NCT02578368
    PubMed
  • 37 Wang Y, Yu YY, Li W. et al. A phase II trial of Xeloda and oxaliplatin (XELOX) neo-adjuvant chemotherapy followed by surgery for advanced gastric cancer patients with para-aortic lymph node metastasis. Cancer Chemother Pharmacol 2014; 73 (06) 1155-1161
    CrossrefPubMedSearch in Google Scholar
  • 38 Kodera Y, Ito S, Mochizuki Y. et al; Chubu Clinical Oncology Group. A phase II study of radical surgery followed by postoperative chemotherapy with S-1 for gastric carcinoma with free cancer cells in the peritoneal cavity (CCOG0301 study). Eur J Surg Oncol 2009; 35 (11) 1158-1163
    CrossrefPubMedSearch in Google Scholar
  • 39 Kodera Y, Ito S, Mochizuki Y. et al. Long-term follow up of patients who were positive for peritoneal lavage cytology: final report from the CCOG0301 study. Gastric Cancer 2012; 15 (03) 335-337
    CrossrefPubMedSearch in Google Scholar
  • 40 Markar SR, Mikhail S, Malietzis G. et al. Influence of surgical resection of hepatic metastases from gastric adenocarcinoma on long-term survival: systematic review and pooled analysis. Ann Surg 2016; 263 (06) 1092-1101
    CrossrefPubMedSearch in Google Scholar
  • 41 Sohal DPS, Willingham FF, Falconi M, Raphael KL, Crippa S. Pancreatic adenocarcinoma: improving prevention and survivorship. Am Soc Clin Oncol Educ Book 2017; 37 (37) 301-310
    CrossrefPubMedSearch in Google Scholar
  • 42 Conroy T, Desseigne F, Ychou M. et al; Groupe Tumeurs Digestives of Unicancer, PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364 (19) 1817-1825
    CrossrefPubMedSearch in Google Scholar
  • 43 Golan T, Hammel P, Reni M. et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med 2019; 381 (04) 317-327
    CrossrefPubMedSearch in Google Scholar
  • 44 Marabelle A, Le DT, Ascierto PA. et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the Phase II KEYNOTE-158 study. J Clin Oncol 2020; 38 (01) 1-10
    CrossrefPubMedSearch in Google Scholar
  • 45 Wu L, Zhu L, Xu K. et al. Clinical significance of site-specific metastases in pancreatic cancer: a study based on both clinical trial and real-world data. J Cancer 2021; 12 (06) 1715-1721
    CrossrefPubMedSearch in Google Scholar
  • 46 Ludmir EB, Sherry AD, Fellman BM. et al. Addition of metastasis-directed therapy to standard-of-care systemic therapy for oligometastatic pancreatic ductal adenocarcinoma (EXTEND): Results of a multicenter, randomized phase II trial. JCO 2024; 42 (03) 603
    CrossrefPubMedSearch in Google Scholar
  • 47 Elamir AM, Karalis JD, Sanford NN. et al. Ablative radiation therapy in oligometastatic pancreatic cancer to delay polyprogression, limit chemotherapy, and improve outcomes. Int J Radiat Oncol Biol Phys 2022; 114 (04) 792-802
    CrossrefPubMedSearch in Google Scholar
  • 48 Lee G, Kim DW, Oladeru OT. et al. Liver metastasis-directed ablative radiotherapy in pancreatic cancer offers prolonged time off systemic therapy in selected patients: data from a multi-institutional retrospective study. Pancreas 2021; 50 (05) 736-743
    CrossrefPubMedSearch in Google Scholar
  • 49 Timmer FEF, Geboers B, Nieuwenhuizen S. et al. Locoregional treatment of metastatic pancreatic cancer utilizing resection, ablation and embolization: a systematic review. Cancers (Basel) 2021; 13 (07) 1608
    CrossrefPubMedSearch in Google Scholar
  • 50 Menon G, Garikipati SC, Roy P. Cholangiocarcinoma. In: StatPearls. StatPearls Publishing; 2024. . Accessed September 11, 2024 at: http://www.ncbi.nlm.nih.gov/books/NBK560708/
    Search in Google Scholar
  • 51 Kelley RK, Ueno M, Yoo C. et al; KEYNOTE-966 Investigators. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023; 401 (10391): 1853-1865
    CrossrefPubMedSearch in Google Scholar
  • 52 Oh DY, Ruth He A, Qin S. et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid 2022; 1 (08) a2200015
    PubMedSearch in Google Scholar
  • 53 Valle J, Wasan H, Palmer DH. et al; ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362 (14) 1273-1281
    CrossrefPubMedSearch in Google Scholar
  • 54 Addition of stereotactic body radiotherapy (SBRT) to systemic chemotherapy in locally advanced cholangiocarcinoma (CC) (ABC-07): Results from a randomized phase II trial. Journal of Clinical Oncology. Accessed November 1, 2024 at: https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.4006
    PubMed
  • 55 Franzese C, Bonu ML, Comito T. et al. Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity. J Cancer Res Clin Oncol 2020; 146 (09) 2289-2297
    CrossrefPubMedSearch in Google Scholar
  • 56 Morino K, Seo S, Yoh T. et al. Proposed definition for oligometastatic recurrence in biliary tract cancer based on results of locoregional treatment: a propensity-score-stratified analysis. Ann Surg Oncol 2020; 27 (06) 1908-1917
    CrossrefPubMedSearch in Google Scholar
  • 57 Sebastian NT, Tan Y, Miller ED. et al. Association of liver-directed local therapy with overall survival in adults with metastatic intrahepatic cholangiocarcinoma. JAMA Netw Open 2019; 2 (09) e1911154
    CrossrefPubMedSearch in Google Scholar
  • 58 Lotfollahzadeh S, Recio-Boiles A, Babiker HM. Liver cancer. In: StatPearls. StatPearls Publishing; 2024. . Accessed September 11, 2024 at: http://www.ncbi.nlm.nih.gov/books/NBK448337/
    Search in Google Scholar
  • 59 Ding J, Wen Z. Survival improvement and prognosis for hepatocellular carcinoma: analysis of the SEER database. BMC Cancer 2021; 21 (01) 1157
    CrossrefPubMedSearch in Google Scholar
  • 60 Finn RS, Qin S, Ikeda M. et al; IMbrave150 Investigators. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 2020; 382 (20) 1894-1905
    CrossrefPubMedSearch in Google Scholar
  • 61 Choi SH, Lee BM, Kim J, Kim DY, Seong J. Efficacy of stereotactic ablative radiotherapy in patients with oligometastatic hepatocellular carcinoma: a phase II study. J Hepatol 2024; 81 (01) 84-92
    CrossrefPubMedSearch in Google Scholar
  • 62 Chen YX, Yang P, Du SS. et al. Stereotactic body radiotherapy combined with sintilimab in patients with recurrent or oligometastatic hepatocellular carcinoma: a phase II clinical trial. World J Gastroenterol 2023; 29 (24) 3871-3882
    CrossrefPubMedSearch in Google Scholar
  • 63 Kim TH, Nam TK, Yoon SM, Kim TH, Choi YM, Seong J. Stereotactic ablative radiotherapy for oligometastatic hepatocellular carcinoma: a multi-institutional retrospective study (KROG 20-04). Cancers (Basel) 2022; 14 (23) 5848
    CrossrefPubMedSearch in Google Scholar
  • 64 Kim S, Lee J, Rim CH. Local treatment of hepatocellular carcinoma with oligometastases: a systematic review and meta-analysis. Cancers (Basel) 2023; 15 (13) 3467
    CrossrefPubMedSearch in Google Scholar
  • 65 Wang J, Li S, Liu Y, Zhang C, Li H, Lai B. Metastatic patterns and survival outcomes in patients with stage IV colon cancer: a population-based analysis. Cancer Med 2020; 9 (01) 361-373
    CrossrefPubMedSearch in Google Scholar
  • 66 Guidelines With Evidence Blocks. . Colon. NCCN. Accessed September 11, 2024 at: https://www.nccn.org/guidelines/guidelines-with-evidence-blocks
    PubMed
  • 67 Van Cutsem E, Köhne CH, Láng I. et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29 (15) 2011-2019
    CrossrefPubMedSearch in Google Scholar
  • 68 Lenz HJ, Van Cutsem E, Luisa Limon M. et al. First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the Phase II CheckMate 142 Study. J Clin Oncol 2022; 40 (02) 161-170
    CrossrefPubMedSearch in Google Scholar
  • 69 Aloia TA, Vauthey JN, Loyer EM. et al. Solitary colorectal liver metastasis: resection determines outcome. Arch Surg 2006; 141 (05) 460-466 , discussion 466–467
    CrossrefPubMedSearch in Google Scholar
  • 70 Kanas GP, Taylor A, Primrose JN. et al. Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin Epidemiol 2012; 4: 283-301
    CrossrefPubMedSearch in Google Scholar
  • 71 Boudjema K, Locher C, Sabbagh C. et al; METASYNC Study group. Simultaneous versus delayed resection for initially resectable synchronous colorectal cancer liver metastases: a prospective, open-label, randomized, controlled trial. Ann Surg 2021; 273 (01) 49-56
    CrossrefPubMedSearch in Google Scholar
  • 72 Tanis E, Nordlinger B, Mauer M. et al. Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983. Eur J Cancer 2014; 50 (05) 912-919
    CrossrefPubMedSearch in Google Scholar
  • 73 Kobiela J, Spychalski P, Marvaso G. et al. Ablative stereotactic radiotherapy for oligometastatic colorectal cancer: systematic review. Crit Rev Oncol Hematol 2018; 129: 91-101
    CrossrefPubMedSearch in Google Scholar
  • 74 Comito T, Cozzi L, Clerici E. et al. Stereotactic ablative radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach. BMC Cancer 2014; 14 (01) 619
    CrossrefPubMedSearch in Google Scholar
  • 75 Sutera P, Kalash R, Clump DA. et al. Stereotactic ablative radiation therapy for unresectable colorectal oligometastases. Adv Radiat Oncol 2018; 4 (01) 57-62
    CrossrefPubMedSearch in Google Scholar
  • 76 Scorsetti M, Comito T, Tozzi A. et al. Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer. J Cancer Res Clin Oncol 2015; 141 (03) 543-553
    CrossrefPubMedSearch in Google Scholar
  • 77 Cho JH, Kim S, Namgung M. et al. The prognostic importance of the number of metastases in pulmonary metastasectomy of colorectal cancer. World J Surg Oncol 2015; 13 (01) 222
    CrossrefPubMedSearch in Google Scholar
  • 78 Salah S, Watanabe K, Welter S. et al. Colorectal cancer pulmonary oligometastases: pooled analysis and construction of a clinical lung metastasectomy prognostic model. Ann Oncol 2012; 23 (10) 2649-2655
    CrossrefPubMedSearch in Google Scholar
  • 79 Treasure T, Farewell V, Macbeth F. et al; PulMiCC Trial Group. Pulmonary Metastasectomy versus Continued Active Monitoring in Colorectal Cancer (PulMiCC): a multicentre randomised clinical trial. Trials 2019; 20 (01) 718
    CrossrefPubMedSearch in Google Scholar
  • 80 Nicosia L, Franceschini D, Perrone-Congedi F. et al. A multicenter LArge retrospectIve daTabase on the personalization of stereotactic ABlative radiotherapy use in lung metastases from colon-rectal cancer: The LaIT-SABR study. Radiother Oncol 2022; 166: 92-99
    CrossrefPubMedSearch in Google Scholar
  • 81 Ferguson J, Alzahrani N, Zhao J. et al. Long term results of RFA to lung metastases from colorectal cancer in 157 patients. Eur J Surg Oncol 2015; 41 (05) 690-695
    CrossrefPubMedSearch in Google Scholar
  • 82 Franko J, Shi Q, Meyers JP. et al; Analysis and Research in Cancers of the Digestive System (ARCAD) Group. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol 2016; 17 (12) 1709-1719
    CrossrefPubMedSearch in Google Scholar
  • 83 Cashin PH, Mahteme H, Spång N. et al. Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: a randomised trial. Eur J Cancer 2016; 53: 155-162
    CrossrefPubMedSearch in Google Scholar
  • 84 Quénet F, Elias D, Roca L. et al; UNICANCER-GI Group and BIG Renape Group. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2021; 22 (02) 256-266
    CrossrefPubMedSearch in Google Scholar
  • 85 Guren MG, Aagnes B, Nygård M, Dahl O, Møller B. Rising incidence and improved survival of anal squamous cell carcinoma in Norway, 1987-2016. Clin Colorectal Cancer 2019; 18 (01) e96-e103
    CrossrefPubMedSearch in Google Scholar
  • 86 Rao S, Sclafani F, Eng C. et al. International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct. J Clin Oncol 2020; 38 (22) 2510-2518
    CrossrefPubMedSearch in Google Scholar
  • 87 Holliday EB, Lester SC, Harmsen WS. et al. Extended-field chemoradiation therapy for definitive treatment of anal canal squamous cell carcinoma involving the para-aortic lymph nodes. Int J Radiat Oncol Biol Phys 2018; 102 (01) 102-108
    CrossrefPubMedSearch in Google Scholar
  • 88 Lo WM, Dogeas E, Etherington MS. et al. Long-term overall survival in patients undergoing liver resection for metastatic anal squamous cell carcinoma. J Surg Oncol 2024; 129 (03) 568-573
    CrossrefPubMedSearch in Google Scholar
  • 89 Pawlik TM, Gleisner AL, Bauer TW. et al. Liver-directed surgery for metastatic squamous cell carcinoma to the liver: results of a multi-center analysis. Ann Surg Oncol 2007; 14 (10) 2807-2816
    CrossrefPubMedSearch in Google Scholar
  • 90 Wind KL, Serup-Hansen E, Havelund BM. et al. Definitive therapy for squamous cell carcinoma of the anus with synchronous metastases - a report from the Danish Anal Cancer Group. Acta Oncol 2022; 61 (03) 321-327
    CrossrefPubMedSearch in Google Scholar
  • 91 Evesque L, Benezery K, Follana P. et al. Multimodal therapy of squamous cell carcinoma of the anus with distant metastasis: a single-institution experience. Dis Colon Rectum 2017; 60 (08) 785-791
    CrossrefPubMedSearch in Google Scholar
  • 92 Eng C, Chang GJ, You YN. et al. The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal. Oncotarget 2014; 5 (22) 11133-11142
    CrossrefPubMedSearch in Google Scholar
  • 93 Study Details | Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body | ClinicalTrials.gov. Accessed September 11, 2024 at: https://clinicaltrials.gov/study/NCT04248452
    PubMed
  • 94 Study Details | Surgical Resection Plus Chemotherapy Versus Chemotherapy Alone in Oligometastatic Stage IV Gastric Cancer | ClinicalTrials.gov. Accessed September 11, 2024 at: https://clinicaltrials.gov/study/NCT03042169
    PubMed
  • 95 Study Details | Chemotherapy Alone Versus Surgery Plus Chemotherapy for Distal Gastric Cancer With One Non-curable Factor | ClinicalTrials.gov. Accessed September 11, 2024 at: https://clinicaltrials.gov/study/NCT03399253
    PubMed
  • 96 Study Details | Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer | ClinicalTrials.gov. Accessed September 10, 2024 at: https://clinicaltrials.gov/study/NCT03161522
    PubMed
  • 97 Study Details | A Clinical Study Of Camrelizumab With Or Without Radiotherapy In The Treatment Of Esophageal Cancer | ClinicalTrials.gov. Accessed September 11, 2024 at: https://clinicaltrials.gov/study/NCT04512417
    PubMed
  • 98 Study Details | PD-1 Antibody Combined With Modified FLOT Regimen in the Treatment of Unresectable Locally Advanced or Limited Metastatic Gastric Cancer | ClinicalTrials.gov. Accessed September 11, 2024 at: https://clinicaltrials.gov/study/NCT04510064
    PubMed
  • 99 Jo P, Ghadimi M, Pelzer U. et al. METAPANC, intensified treatment in patients with oligometastatic pancreatic cancer: Multimodal surgical treatment versus systemic chemotherapy alone—A prospective randomized controlled multicenter phase III trial. JCO 2024; 42 (16) TPS4207-TPS4207
    CrossrefPubMedSearch in Google Scholar
  • 100 Study Details | Chemotherapy and Surgical Resection in Patients With Hepatic Oligometastatic Adenocarcinoma of the Pancreas | ClinicalTrials.gov. Accessed September 11, 2024 at: https://www.clinicaltrials.gov/study/NCT04617457
    PubMed
  • 101 Study Details | Standard of Care Chemotherapy With or Without Stereotactic Body Radiation Therapy for Oligometastatic Pancreatic Cancer | ClinicalTrials.gov. Accessed September 11, 2024 at: https://clinicaltrials.gov/study/NCT04975516
    PubMed
  • 102 Wei M, Shi S, Hua J, Xu J, Yu X. Chinese Study Group for Pancreatic Cancer (CSPAC). Simultaneous resection of the primary tumour and liver metastases after conversion chemotherapy versus standard therapy in pancreatic cancer with liver oligometastasis: protocol of a multicentre, prospective, randomised phase III control trial (CSPAC-1). BMJ Open 2019; 9 (12) e033452
    CrossrefPubMedSearch in Google Scholar
  • 103 Study Details | Surgery for Liver Metastases From PDAC | ClinicalTrials.gov. Accessed September 11, 2024 at: https://clinicaltrials.gov/study/NCT05271110
    PubMed
  • 104 Study Details | Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC | ClinicalTrials.gov. Accessed September 11, 2024 at: https://www.clinicaltrials.gov/study/NCT05917431
    PubMed
  • 105 Study Details | Chemotherapy and Maximal Tumor Debulking of Multi-organ Colorectal Cancer Metastases | ClinicalTrials.gov. Accessed September 11, 2024 at: https://clinicaltrials.gov/study/nct01792934
    PubMed
  • 106 Study Details | Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study | ClinicalTrials.gov. Accessed September 11, 2024. https://www.clinicaltrials.gov/study/NCT05673148
    PubMed
  • 107 Study Details | COLLISION Trial - Colorectal Liver Metastases: Surgery vs Thermal Ablation | ClinicalTrials.gov. Accessed September 11, 2024 at: https://www.clinicaltrials.gov/study/NCT03088150
    PubMed
  • 108 Study Details | Comparison of Hepatectomy and Local Ablation for Resectable Synchronous and Metachronous Colorectal Liver Metastasis | ClinicalTrials.gov. Accessed September 11, 2024 at: https://www.clinicaltrials.gov/study/NCT02886104
    PubMed
  • 109 Study Details | Stereotactic Body Radiation Therapy vs. Microwave Ablation for Colorectal Cancer Patients With Metastatic Disease in the Liver | ClinicalTrials.gov. Accessed September 11, 2024 at: https://clinicaltrials.gov/study/NCT03654131
    PubMed
  • 110 Study Details | Consolidative Radiotherapy Plus Maintenance Chemotherapy for Metastatic Colorectal Cancer | ClinicalTrials.gov. Accessed September 11, 2024 at: https://clinicaltrials.gov/study/nct03142282
    PubMed
  • 111 Study Details | COLLISION XL: Unresectable Colorectal Liver Metastases (3–5cm): Stereotactic Body Radiotherapy vs. Microwave Ablation | ClinicalTrials.gov. Accessed September 11, 2024 at: https://clinicaltrials.gov/study/NCT04081168
    PubMed
  • 112 Study Details | CRT Versus Surgery for Retroperitoneal or Paraaortic Lymph Node Recurrence of CRC | ClinicalTrials.gov. Accessed September 11, 2024 at: https://clinicaltrials.gov/study/NCT03725254
    PubMed
  • 113 Study Details | Liver Transplantation and Colorectal Cancer | ClinicalTrials.gov. Accessed September 11, 2024 at: https://clinicaltrials.gov/study/NCT01479608
    PubMed
  • 114 Study Details | The Swedish Study of Liver Transplantation for Non-resectable Colorectal Cancer Metastases | ClinicalTrials.gov. Accessed September 11, 2024 at: https://www.clinicaltrials.gov/study/NCT04161092
    PubMed
  • 115 Study Details | Liver Transplantation in Patients With Unresectable Colorectal Liver Metastases Treated by Chemotherapy | ClinicalTrials.gov. Accessed September 11, 2024 at: https://www.clinicaltrials.gov/study/NCT02597348
    PubMed
  • 116 Study Details | RESOLUTE Trial Aims to Investigate the Value of Adding Local Ablative Treatment to Standard Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer | ClinicalTrials.gov. Accessed September 11, 2024 at: https://clinicaltrials.gov/study/NCT05862051
    PubMed